GlassScriptPhysician profile
Jyothi A Kadambi
NPI 1215919840
$2,614.38
in general payments reported to CMS, 2019-2025
24 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $372 · 2023: $520 · 2024: $1,032 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.16 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $319.62 | 2022-2025 | Airsupra, Breztri, Andexxa |
| Pfizer INC. | $284.55 | 2022-2025 | |
| Lilly USA, LLC | $277.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $241.76 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $222.86 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $115.38 | 2024 | Signia |
| Abbvie INC. | $106.03 | 2023-2025 | Qulipta, Ubrelvy |
| Astellas Pharma US INC | $99.35 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $94.70 | 2024-2025 | Gvoke Hypopen |
| Abbott Laboratories | $66.01 | 2022-2023 | Freestyle Libre 2 |
| Tolmar, INC. | $52.07 | 2024-2025 | Jatenzo |
| Ucb, INC. | $51.78 | 2022 | |
| Genzyme Corporation | $35.25 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $32.46 | 2024-2025 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $31.77 | 2024 | |
| Neurocrine Biosciences, INC. | $30.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.88 | 2022 | |
| Acclarent, INC | $23.31 | 2023 | Relieva Spinplus |
| Biohaven Pharmaceutical Holding Company LTD. | $23.15 | 2022 | |
| Esperion Therapeutics, INC. | $22.88 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $22.74 | 2023 | |
| Sumitomo Pharma America, INC. | $20.96 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $17.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothi Kadambi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.